Vaxart, Inc. financial data

Symbol
VXRT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
170 Harbor Way, Suite 300, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Aviragen Therapeutics, Inc. (to 2/15/2018), Biota Pharmaceuticals, Inc. (to 4/13/2016), NABI BIOPHARMACEUTICALS (to 11/8/2012), NABI BIOPHARMACEUTICALS (to 6/29/2010), NABI /DE/ (to 2/14/2002), NORTH AMERICAN BIOLOGICALS INC (to 2/14/1996)
Latest financial report
10-K - Q4 2024 - Mar 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 125 % -72.8%
Debt-to-equity 104 % +116%
Return On Equity -102 % +6.14%
Return On Assets -50 % +31.8%
Operating Margin -231 % +79.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 228M shares +31.1%
Common Stock, Shares, Outstanding 228M shares +48.4%
Entity Public Float 151M USD +36.7%
Common Stock, Value, Issued 23K USD +53.3%
Weighted Average Number of Shares Outstanding, Basic 202M shares +39.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 28.7M USD +289%
Research and Development Expense 74.2M USD +8.91%
General and Administrative Expense 20.8M USD -7.99%
Operating Income (Loss) -66.3M USD +20.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -66.7M USD +18.9%
Income Tax Expense (Benefit) 260K USD -0.38%
Net Income (Loss) Attributable to Parent -66.9M USD +18.8%
Earnings Per Share, Basic -0.33 USD/shares +42.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22M USD -33.5%
Cash, Cash Equivalents, and Short-term Investments 51.7M USD +30.2%
Accounts Receivable, after Allowance for Credit Loss, Current 5.76M USD +91.5%
Other Assets, Current 318K USD -4.51%
Assets, Current 68.3M USD +49.9%
Property, Plant and Equipment, Net 8.71M USD -25.8%
Operating Lease, Right-of-Use Asset 20.4M USD -17.9%
Intangible Assets, Net (Excluding Goodwill) 3.56M USD -17.1%
Goodwill 4.51M USD 0%
Other Assets, Noncurrent 839K USD -9.4%
Assets 166M USD +81.2%
Accounts Payable, Current 6.96M USD +340%
Employee-related Liabilities, Current 5.09M USD +11.2%
Accrued Liabilities, Current 11.4M USD +102%
Liabilities, Current 90.9M USD +562%
Operating Lease, Liability, Noncurrent 14.4M USD -16.9%
Other Liabilities, Noncurrent 439K USD +49.8%
Liabilities 107M USD +216%
Accumulated Other Comprehensive Income (Loss), Net of Tax 4K USD
Retained Earnings (Accumulated Deficit) -477M USD -16.3%
Stockholders' Equity Attributable to Parent 58.9M USD +1.94%
Liabilities and Equity 166M USD +81.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.2M USD +13.4%
Net Cash Provided by (Used in) Financing Activities 18.2M USD +1181%
Net Cash Provided by (Used in) Investing Activities -5.02M USD -120%
Common Stock, Shares Authorized 350M shares +40%
Common Stock, Shares, Issued 228M shares +48.2%
Common Stock, Par or Stated Value Per Share 0.1 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.02M USD -431%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.2M USD -27.4%
Deferred Tax Assets, Valuation Allowance 94.1M USD +14.1%
Deferred Tax Assets, Gross 101M USD +11.4%
Operating Lease, Liability 17.5M USD -12.8%
Depreciation 3.7M USD -2.63%
Payments to Acquire Property, Plant, and Equipment 131K USD -89.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -66.9M USD +18.5%
Lessee, Operating Lease, Liability, to be Paid 21.5M USD -16.9%
Property, Plant and Equipment, Gross 19.2M USD +3.51%
Operating Lease, Liability, Current 3.08M USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.03M USD +11.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.51M USD +2.97%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.96M USD -31.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.21M USD +3.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 8.54M USD +30%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.39M USD +3.5%
Operating Lease, Payments 2M USD +81.8%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 700K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 6.41M USD -17.1%
Share-based Payment Arrangement, Expense 11.5M USD -18.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%